Glaukos (GKOS) Short term Debt (2014 - 2021)

Glaukos (GKOS) reported Short term Debt of $279.3 million for Q2 2021, little changed quarter-over-quarter from $279.0 million in Q1 2021.

Glaukos (GKOS) Short term Debt (2014 - 2021) Analysis & Trends

Glaukos (GKOS) has 5 years of Short term Debt data on file, last reported at $279.3 million in Q2 2021.

Short term Debt for Q2 2021 came in at $279.3 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $279.3 million (changed N/A YoY), and the FY2020 annual result was $89.2 million, changed N/A from the prior year.
Short term Debt was little changed at $279.3 million in Q2 2021 per GKOS's latest filing, from $279.0 million in the prior quarter.
Over five years, Short term Debt peaked at $279.3 million in Q2 2021 and troughed at $89.2 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Glaukos	7.55 Bn	7.45 Bn	117.23 Mn

Download Data